SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:8dbe445c-8f73-4cba-be17-28bd5e1edb82"
 

Search: onr:"swepub:oai:lup.lub.lu.se:8dbe445c-8f73-4cba-be17-28bd5e1edb82" > Pre-treatment healt...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Lindberg, ÅsaLund University,Lunds universitet,Infektionsmedicin,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Infection Medicine (BMC),Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Halmstad County Hospital,Lund Univ, Dept Infect Dis, Lund, Sweden.;Halland Hosp, Div Med, S-30185 Halmstad, Sweden. (author)

Pre-treatment health-related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma : The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience

  • Article/chapterEnglish2022

Publisher, publication year, extent ...

  • 2021-11-10
  • Wiley,2022

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:8dbe445c-8f73-4cba-be17-28bd5e1edb82
  • https://lup.lub.lu.se/record/8dbe445c-8f73-4cba-be17-28bd5e1edb82URI
  • https://doi.org/10.1002/hon.2940DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-470097URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Mantle cell lymphoma (MCL) is a rare, often aggressive type of B-cell lymphoma with poor survival and no cure. Cancer and cancer treatment has a negative impact on health-related quality of life (HRQOL) both during active disease and in the long term, and improvement of HRQOL is a crucial objective of cancer therapy in older patients and no curative intent. Baseline HRQOL has in other lymphoma populations been shown to be predictive of outcome. Here, we explored HRQOL, and its association with survival, by the EORTC QLQ-C30 questionnaire, before, during and after chemotherapy in a patient cohort with MCL, treated within the NLG-MCL4 trial, designed to evaluate the addition of lenalidomide (LEN) to rituximab-bendamustine (R-B) as first-line treatment. Fifty-one patients were enrolled, median age was 71 years (range 62–84), 37 were men (73%). Pre-treatment HRQOL was similar to scores from the reference population with healthy individuals. During treatment, HRQOL deteriorated, but reverted to the same level as the reference population after treatment. There was a correlation between physical function (p = 0.001) and role function (p = 0.006) at baseline and WHO performance status, but not with other clinical or genetic prognostic factors. None of the baseline factors were predictive for treatment related to HRQOL in this cohort. Pre-treatment physical (p = 0.011) and role function (p = 0.032) were independent factors associated with overall survival, and physical function (p = 0.002) was also associated with progression free survival. These findings may possibly be used to design support during treatment and improve rehabilitation. Further investigations are needed for assessment of long-term HRQOL.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Eskelund, Christian WintherCopenhagen University Hospital,University of Copenhagen,Rigshosp, Dept Haematol, Copenhagen, Denmark.;Univ Copenhagen, Fac Hlth Sci, Biotech Res & Innovat Ctr, Copenhagen, Denmark. (author)
  • Albertsson-Lindblad, AlexandraLund University,Lunds universitet,Lymfom - Klinisk forskning,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Lymphoma - Clinical Research,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Skåne University Hospital,Lund Univ, Div Oncol, Lund, Sweden.;Skane Univ Hosp, Lund, Sweden.(Swepub:lu)med-aab (author)
  • Kolstad, ArneOslo university hospital,Oslo Univ Hosp, Dept Oncol, Oslo, Norway. (author)
  • Laurell, AnnaUppsala universitet,Experimentell och klinisk onkologi(Swepub:uu)annajohn (author)
  • Räty, RiikkaHelsinki University Central Hospital,Helsinki Univ Hosp, Dept Haematol, Helsinki, Finland. (author)
  • Grønbæk, KirstenUniversity of Copenhagen,Copenhagen University Hospital,Rigshosp, Dept Haematol, Copenhagen, Denmark.;Univ Copenhagen, Fac Hlth Sci, Biotech Res & Innovat Ctr, Copenhagen, Denmark. (author)
  • Geisler, Christian HartmannUniversity of Copenhagen,Copenhagen University Hospital,Rigshosp, Dept Haematol, Copenhagen, Denmark.;Univ Copenhagen, Fac Hlth Sci, Biotech Res & Innovat Ctr, Copenhagen, Denmark. (author)
  • Jerkeman, MatsLund University,Lunds universitet,Lymfom - Klinisk forskning,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Lymphoma - Clinical Research,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Skåne University Hospital,Lund Univ, Div Oncol, Lund, Sweden.;Skane Univ Hosp, Lund, Sweden.(Swepub:lu)onk-mje (author)
  • InfektionsmedicinSektion III (creator_code:org_t)

Related titles

  • In:Hematological Oncology: Wiley40:1, s. 23-310278-02321099-1069

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view